Arcturus Therapeutics (ARCT) Stock Rating Upgraded by Zacks Investment Research

Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. “

Get Arcturus Therapeutics alerts:

Several other research analysts have also recently weighed in on ARCT. Roth Capital restated a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, February 20th. Laidlaw initiated coverage on Arcturus Therapeutics in a report on Tuesday, February 19th. They issued a “buy” rating for the company. Finally, ValuEngine lowered Arcturus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Arcturus Therapeutics has a consensus rating of “Buy” and an average target price of $5.25.

Shares of ARCT stock traded down $0.13 during trading hours on Thursday, reaching $4.60. The company’s stock had a trading volume of 1,319 shares, compared to its average volume of 38,135. The firm has a market cap of $48.78 million, a P/E ratio of -1.30 and a beta of 2.14. Arcturus Therapeutics has a one year low of $4.11 and a one year high of $10.00.

A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its stake in shares of Arcturus Therapeutics by 91.7% in the third quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock worth $148,000 after acquiring an additional 8,008 shares during the period. BlackRock Inc. purchased a new stake in shares of Arcturus Therapeutics in the second quarter worth about $169,000. Worth Venture Partners LLC purchased a new stake in shares of Arcturus Therapeutics in the third quarter worth about $290,000. Finally, ARK Investment Management LLC lifted its position in shares of Arcturus Therapeutics by 45.0% in the third quarter. ARK Investment Management LLC now owns 773,772 shares of the biotechnology company’s stock worth $6,840,000 after buying an additional 239,999 shares in the last quarter. 10.29% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Featured Article: Return on Investment (ROI)

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com